Cobimetinib + Vemurafenib in Patients With

Authors

• Samantha A Diamond-Rossi
• Michael Rothe
• Elizabeth Garrett-Mayer
• Evan Pisick
• Jonathan Bleeker
• Apar Kishor Ganti
• Funda Meric-Bernstam
• Justin T Moyers
• Suresh G. Nair MD, Lehigh Valley Health NetworkFollow
• Kunal C Kadakia
• Nitin Rohatgi
• Vaibhav Sahai
• Namrata Vijayvergia
• Philip J Gold
• Manish R Sharma
• Dominique C Hinshaw
• Abigail Gregory
• Gina N Grantham
• Susan Halabi
• Richard L Schilsky

Publication/Presentation Date

10-1-2026

Abstract

PURPOSE: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with advanced thyroid (TC) or biliary tract cancer (BTC) with

METHODS: Eligible patients had measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). Both cohorts expanded to stage II but closed before reaching the target sample size by pharmaceutical company request; inferences are based on thresholds set forth in the protocol to maintain the α level. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of SD, and safety.

RESULTS: Patients with TC (N = 22; n = 16 evaluable) or BTC (N = 18; n = 15 evaluable) with

CONCLUSION: The combination of C + V met the prespecified criteria to declare a signal of activity in patients with TC and BTC with

Volume

10

Issue

10

First Page

2600703

Last Page

2600703

ISSN

2473-4284

Published In/Presented At

Diamond-Rossi, S. A., Rothe, M., Garrett-Mayer, E., Pisick, E., Bleeker, J., Ganti, A. K., Meric-Bernstam, F., Moyers, J. T., Nair, S. G., Kadakia, K. C., Rohatgi, N., Sahai, V., Vijayvergia, N., Gold, P. J., Sharma, M. R., Hinshaw, D. C., Gregory, A., Grantham, G. N., Halabi, S., & Schilsky, R. L. (2026). Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO precision oncology, 10(10), e2600703. https://doi.org/10.1200/PO-26-00703

PubMedID

42886887

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article